Patsnap, the AI-native innovation intelligence company for IP and R&D teams, today released “State of Pharma Intelligence 2026: The Confidence to Act“, a benchmark report on how pharma teams use and trust AI in R&D, competitive intelligence and business development decisions. The report draws on responses from 130 senior leaders at Director level or above across the United States, the United Kingdom, Germany, Switzerland, and France, spanning drug developers, CDMOs/CMOs, CROs, and consulting and professional services firms. The survey was fielded in August 2026 in partnership with NewtonX.

Patsnap commissioned the research to understand how AI is influencing decisions across pharma R&D and business development, what builds confidence in its output, and where intelligence workflows fall short. A central finding of the survey is that speed is limited less by finding the signal, than by trusting it. Among pharma teams using AI, internal alignment (48%) and validation time (26%) are the leading constraints on how quickly they can screen a potential partner, while only 20% say speed of signal detection is their biggest gap.

“Pharma has embraced AI cautiously, and the lag in confidence in autonomous decision-making has left teams in a lose-lose position: decide fast and risk backing the wrong candidate, or wait for proof and lose the right one to a rival. The teams that close that confidence gap between AI output and decision will set the pace,” said Mark Davies, Head of Product, Life Sciences, Patsnap.

Key findings include:

  • AI is moving beyond efficiency to influence pharma decisions, but human oversight remains critical: 92% of the 130 leaders surveyed can identify a decision in the past six months where AI changed the outcome rather than simply accelerating the process, including pipeline tracking, portfolio prioritization, target assessment and candidate selection. Yet 84% say expert or analyst review precedes AI-informed decisions, 65% rely on semi-automated workflows, and only two respondents act on AI outputs without further validation.

  • China is seen as the biggest external-innovation opportunity, but visibility remains a challenge: 45% of leaders surveyed name China the top external-innovation opportunity for the next five years, ahead of North America (30%), yet only 22% are confident in their visibility into China’s pipeline and licensing activity. Source credibility is the leading barrier, cited by 47% of respondents who identified a barrier.

  • Alignment and verification, rather than signal detection, set the pace of partner screening: 77% of respondents need three weeks or more to produce initial screening intelligence on a potential partner, 65% rely on semi-automated workflows, and judging which candidates will succeed is a bigger gap than identifying them early (38% vs. 20%).

“Teams report a smaller gap in spotting a signal early than in verifying it and aligning behind it. That verification layer is the next frontier we expect AI to take on,” continued Davies.

In pharma’s most competitive areas, including licensing, asset scouting, and partner screening, speed depends on how quickly teams can turn scientific, clinical, patent, and commercial evidence into a decision they can defend. Patsnap’s AI agents and analytics tools support IP and R&D teams as they make those decisions, and this research identifies where trusted, source-linked AI for pharma decisions matters most.

That is what Patsnap is built for: Patsnap Synapse links drug, target, clinical trial, patent and deal data in one place, and Patsnap Eureka Life Sciences adds AI agents that answer questions and extract evidence from that data, with every output traceable to its source.

Several questions remain open for the industry to watch: whether trust in AI output rises as teams gain experience with it, whether consistent validation practices lead to greater confidence in it, and whether screening and decision timelines shorten as workflows move beyond semi-automation. The survey establishes a baseline Patsnap will track annually: whether trust in AI output rises with experience, whether consistent validation builds confidence, and whether screening timelines shorten as automation matures.

Additional findings on trust, validation, AI staffing, and innovation in China:

  • Trust in AI output is the most common bottleneck to getting more value from AI, named by 31% of respondents, ahead of data quality (23%) and governance (19%).

  • Surveyed organizations using three or more validation methods report considerable or complete trust in AI output more than three times as often as those using one or none (37% vs. 11%; association only).

  • Respondents at organizations with dedicated AI/ML headcount report advanced automation three times as often as those without it (27% vs. 9%; association only).

  • Only 9% of surveyed leaders treat China intelligence as a core decision input, although nearly two-thirds increased their investment in understanding China over the past year.

Download the full report: “State of Pharma Intelligence 2026: The Confidence to Act”

About Patsnap

Patsnap is a global AI-native innovation intelligence platform for IP, R&D and life sciences teams. Founded in Singapore in 2007, Patsnap combines task-specific AI agents with the most comprehensive innovation dataset available enabling teams to search, analyze, draft and validate faster, with every answer traced to its source. Through APIs, MCP and enterprise integrations, customers can also bring Patsnap intelligence directly into their own tools, workflows and AI assistants. More than 18,000 enterprises, law firms and research institutions in over 50 countries rely on Patsnap, including one-third of the world’s largest R&D spenders. Learn more at patsnap.com.

Media gallery

About The Author
Business Wire